Enhanced In Vitro/In Vivo Cytotoxicity Against Burkitt Lymphoma/Primary Mediastinal Large B Cell Lymphoma by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) Alone or in Combination with Obinutuzumab
Author Type(s)
Faculty, Resident/Fellow
Document Type
Abstract
Publication Date
7-2018
DOI
10.1158/1538-7445.AM2018-1788
Journal Title
Cancer Research
Department
Pediatrics
Second Department
Health Behavior and Community Health
Disciplines
Medicine and Health Sciences
Recommended Citation
Tiwari, A. A., Edani, D., Azmy, C., Ayello, J., Klein, C., & Cairo, M. S. (2018). Enhanced In Vitro/In Vivo Cytotoxicity Against Burkitt Lymphoma/Primary Mediastinal Large B Cell Lymphoma by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) Alone or in Combination with Obinutuzumab. Cancer Research, 78 (13 Suppl.), 1778. https://doi.org/10.1158/1538-7445.AM2018-1788
COinS
